CSL Behring revenue was $7.85 b in FY, 2020 which is a (7.0%) year over year increase from the previous period.
CSL Behring revenue breakdown by business segment: 51.1% from Immunoglobulins, 14.3% from Hemophilia, 8.1% from Albumin, 21.6% from Specialty and 4.8% from Other
|FY, 2019||FY, 2018||FY, 2020|
|Immunoglobulins||3.54 b||3.15 b||4.01 b|
|Hemophilia||1.05 b||1.11 b||1.12 b|
|Albumin||1.02 b||921 m||640 m|
|Specialty||1.57 b||1.49 b||1.7 b|
|Other||158.9 m||158 m||380.7 m|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.